Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease

Open access

Abstract

Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain neurodegenerative diseases, one being Alzheimer’s disease (AD). The efficacy of conventional antidepressants to treat depression in AD is conflicting, especially regarding selective serotonin reuptake inhibitors (SSRIs). A recent systemic review and meta-analysis of 25 randomized controlled trials including fourteen antidepressant medications showed no high efficacy in treating AD patients’ symptoms. However, ketamine, a nonselective N-methyl-D-aspartate (NMDA) receptor antagonist, can mediate a wide range of pharmacological effects, including neuroprotection, anti-inflammatory and anticancer properties, multimodal analgesia, and treatment of depression, suicidal attempts, and status epilepticus. Esketamine, which is ketamine formulated as a nasal spray, was approved by the Federal Drug Administration (FDA) in March 2019 as an adjuvant drug to treat treatment-resistant depression. NMDA receptor antagonists treat AD through offsetting AD-related pathological stimulation of subtypes of glutamate receptors in the central nervous system. Recent clinical findings suggest that ketamine may provide neuroprotection and reduce neuropsychiatric symptoms associated with AD. In the present investigation, we evaluate the potential role of ketamine and its postulated mechanism in AD management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/neurolint14020025

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 6

  1. Chand, S.P., and Arif, H. (2022, February 07). Depression, StatPearls, Available online: http://www.ncbi.nlm.nih.gov/books/NBK430847/.
  2. (2022, February 07). Ketamine: A Neglected Therapy for Alzheimer Disease, Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667975/.
  3. Kuns, B., Rosani, A., and Varghese, D. (2022, February 07). Memantine, StatPearls, Available online: http://www.ncbi.nlm.nih.gov/books/NBK500025/.
  4. (2022, February 07). Memantine in Moderate-to-Severe Alzheimer’s Disease—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/12672860/.
  5. (2022, February 07). Neuroinflammation and Microglial Activation in Alzheimer’s Disease: Where Do We Go from Here?—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/33318676/.
  6. (2022, February 07). The Anti-Inflammatory Effects of Ketamine: State of the Art—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/21612145/.

Cited by

See all 41

Metadata

Authors
Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D.
Affiliations
  • Anesthesia Department, Faculty of Medicine, Ain Shams University, Cairo 11517, Egypt
  • Dow University of Health Sciences (PK)
  • Ain Shams University (EG)
  • Louisiana State University Health Sciences Center Shreveport (US)
  • University of the Pacific (US)
Corresponding author
Edinoff, Amber N.
Venue
Neurology International
Publisher
MDPI AG
Published
2022-03-22
Volume
14
Issue
2
Pages
310-321
ISSN
2035-8377 (ISSN-L)
OpenAlex
W4224839098
Cited by
41
References
47
Citations by year
2026: 4 · 2025: 17 · 2024: 11 · 2023: 6 · 2022: 2
FWCI
1.29
Type
journal article
Language
en
Open access
Locations
  • Neurology International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Scholarly Commons (University of the Pacific) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
ketamine, esketamine, Alzheimer's disease, depression, NMDA receptor antagonists, treatment-resistant depression, antidepressant efficacy, neuroprotection, glutamate receptors, neuropsychiatric symptoms, anti-inflammatory activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/neurolint14020025
The paper
Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease. Neurology International. https://doi.org/10.3390/neurolint14020025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.